The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.
Sosei Heptares has developed considerable expertise in GPCRs that has allowed it to attract a string of partners, with Genentech joining Pfizer, AstraZeneca, Allergan, Novartis, and Daiichi-Sankyo, amongst others.
In March it formed a cancer immunotherapy alliance with CRUK and Ono Pharma, in April it licensed an ion channel drug discovery programme to Daiichi Sankyo, and in early May it
separately gave Daiichi Sankyo some succour by backing pexidartinib for a rare condition called tenosynovial giant cell tumour (TGCT). ... tissues. Daiichi Sankyo acquired the drug when it bought Taiwanese firm Plexxikon for almost $1bn in 2011.
Pfizer is just one of Sosei Heptares’ big pharma partners, and the company has also attracted sizeable collaborations with AstraZeneca, Allergan, Novartis, and Daiichi-Sankyo.
Pivotal phase 2 data backs investment. AstraZeneca has the positive pivotal trial it needed to justify its big investment in Daiichi’s HER2-targeting antibody-drug conjugate DS-8201, a rival ... There are no anti-HER2 therapies currently approved for
[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...